This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
BD (BDX) Receives FDA Nod to Address Critical Infusion Needs
by Zacks Equity Research
The latest regulatory clearance for BD's (BDX) Alaris Infusion System is expected to improve healthcare system efficiency via better care coordination and utilization of actionable information.
Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and DexCom (DXCM) have performed compared to their sector so far this year.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
What's in the Cards for Universal Health (UHS) in Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.
Will Boston Scientific (BSX) Beat Q2 Earnings Estimates?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN and other interventional cardiology therapies.
Avantor's (AVTR) New Expansion Plans to Boost Workflow
by Zacks Equity Research
Avantor's (AVTR) latest expansion plans are likely to aid customers in creating customized workflow solutions.
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease
by Zacks Equity Research
Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detection of eye diseases more efficient.
Elevance Health (ELV) Beats on Q2 Earnings, Ups '23 Profit View
by Zacks Equity Research
Elevance Health's (ELV) Q2 results benefit from an expanding customer base and solid pharmacy product revenues. Adjusted net income is expected to be more than $32.85 per share for 2023.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) second-quarter 2023 results are likely to highlight sustained stability across its Clear Aligner business.
Here's Why You Should Add BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Masimo's (MASI) Preliminary Q2 Revenues Dampened by Lower Sales
by Zacks Equity Research
Masimo's (MASI) second-quarter 2023 results are likely to have been dampened by the postponement of orders and increased hospital labor costs, among others.
What's in Store for Thermo Fisher (TMO) in Q2 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) is likely to have generated growth in the second quarter, driven by a favorable business mix and new launches.
Inogen (INGN) Inks Buyout Agreement to Expand Product Portfolio
by Zacks Equity Research
Inogen's (INGN) latest acquisition is expected to leverage its commercial infrastructure and capabilities as well as potentially address a large growing bronchiectasis market.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.
Boston Scientific (BSX) Gets FDA Nod for Vercise Software
by Zacks Equity Research
Boston Scientific's (BSX) Vercise Neural Navigator 5 Software has an improved user interface that presents patient data in an easier-to-understand style and enables better therapy delivery.
UnitedHealth Group (UNH) Q2 Earnings Beat, Boosts '23 EPS View
by Zacks Equity Research
UnitedHealth Group's (UNH) Q2 results benefited on the back of solid contributions from the UnitedHealthcare and Optum segments. Management presently forecasts adjusted net EPS within $24.70-$25.00 for 2023.
Inogen's (INGN) Preliminary Q2 Revenues Dampened by Lower Sales
by Zacks Equity Research
Inogen's (INGN) revenue growth in the second quarter is likely to have been hampered by lower revenues in its business-to-business and direct-to-consumer channels.
Thermo Fisher (TMO) Launches Diomni Enterprise Software
by Zacks Equity Research
Thermo Fisher's (TMO) Diomni Enterprise Software effortlessly connects each individual processing stage to a single, integrated platform.
AngioDynamics (ANGO) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in fourth-quarter fiscal 2023.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
CVS Health (CVS) Launches Caremark Cost Saver With a New Pact
by Zacks Equity Research
CVS Health (CVS) is able to dynamically shop for the lowest price on its clients' behalf with the help of Caremark Cost Saver solution.
VREX vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
VREX vs. BSX: Which Stock Is the Better Value Option?
Illumina's (ILMN) Latest Launch to Boost Genomics Analysis
by Zacks Equity Research
Illumina's (ILMN) DRAGEN v4.2 is expected to improve the identification of genetic disease causes, drug discovery and population genomics.